Rapid Medical - Active Neurovascular Interventional Devices Pioneer

admin12026-04-17 11:33:00

📢 Important Milestones (2026):
In April 2026, Rapid Medical received FDA clearance for TIGERTRIEVER™ 25, the latest addition to its thrombectomy platform for large vessel stroke. In February 2026, the company announced overwhelmingly positive results from the DISTALS trial showing TIGERTRIEVER™ 13 achieved 86.3% successful reperfusion without symptomatic intracranial hemorrhage in medium vessel occlusion (MVO) stroke versus 27.7% with medical management (P < .001).

Company Overview (Updated April 2026)

Rapid Medical is a privately held medical device company headquartered in Yokneam Illit, Israel, with U.S. offices in Southlake, Texas. Founded in 2008, the company pioneered the development of active, controllable neurovascular devices that enable physicians to respond in real-time to patient anatomy during procedures. The company utilizes proprietary manufacturing techniques to create fully visible, remotely adjustable devices for treating ischemic and hemorrhagic stroke.

Mission: To expand what's possible in neurovascular treatment by pioneering advanced interventional devices that treat ischemic and hemorrhagic stroke, enabling physicians to tailor the approach to every patient for better procedural outcomes.

Corporate History and Financing

Funding History

Series A (December 2016): $3.31 million

Series B (July 2017): $9 million (total raised $12.3M)

Series C (April 2019): Completed

Series D (May 2021): Completed

Series D Extension (September 2024): Completed

Series C (August 2025): $20 million led by JAM Capital Partners and MicroPort Scientific Corporation, with participation from Agate JT, RocSon Medtech Fund and existing investors. Proceeds used for completion of TIGER U.S. IDE study and accelerating commercial growth.

Global Expansion

- Israel: Global headquarters and R&D center in Yokneam Illit

- United States: Operations in Southlake, Texas

- Europe: CE Mark approval under EU MDR for multiple products

- Asia-Pacific: Distribution through strategic partnerships including MicroPort

Core Product Portfolio

TIGERTRIEVER™ Revascularization Devices (Ischemic Stroke)

The TIGERTRIEVER™ platform comprises adjustable stent retrievers designed to restore blood flow in acute ischemic stroke:

TIGERTRIEVER™ 13:

- Purpose-built for distal medium vessel occlusions (MVO) in 1.5-3.0 mm vessels

- 0.013" wire-based delivery with 3 mm x 11 mm capture mesh

- Only thrombectomy device that can actively remove tension from vessel during retrieval

- CE Mark and FDA cleared

- DISTALS trial (2026): 86.3% successful reperfusion without sICH vs 27.7% medical management (P < .001)

TIGERTRIEVER™ 17:

- For 2.0-3.5 mm vessels with 17 mm working length

- TIGERTRIEVER™ 17 Ultra variant (K251603) cleared October 2025

TIGERTRIEVER™ 21:

- Standard large vessel device for vessels 2.5-4.0 mm

TIGERTRIEVER™ 25 (April 2026 FDA Clearance):

- Designed for large clot burdens in proximal vessels (ICA, M1)

- 53 mm capture length with real-time force control

- Operator-controlled expansion and distal net to reduce fragmentation

TIGERTRIEVER™ XL:

- Extra-large variant for large vessel occlusions

- CE marked

COMANECI™ Embolization Assist Device (Hemorrhagic Stroke)

The COMANECI™ is the first active, controllable, non-occlusive temporary assist device for wide-necked intracranial aneurysm coiling:

- Provides temporary neck bridging without blocking blood flow (unlike balloons)

- Leaves no permanent implant (unlike stents)

- 85% immediate complete occlusion vs 79% stent-assisted

- 95% successful long-term occlusion with 1% retreatment rate (SUCCESS study)

- CE marked and FDA cleared

DRIVEWIRE™ Steerable Guidewire System (Access)

The DRIVEWIRE™ (formerly COLUMBUS™) is the first steerable guidewire for neurovascular procedures:

DRIVEWIRE™ 14:

- 0.014" steerable guidewire with controllable distal tip

- CE marked and FDA cleared

DRIVEWIRE™ 24 (FDA Cleared 2025):

- 0.024" steerable guidewire with deflectable, mechanically adjustable tip

- CE Mark approved September 2025 under EU MDR

- Successfully used in over 1,000 neurovascular procedures in North America (as of September 2025)

- 94% successful target site reach in multicenter analysis of 176 cases with no device-related complications

Clinical Evidence and Trials (2026)

DISTALS Trial - TIGERTRIEVER™ 13 for MVO Stroke

Study Design: Multicenter, randomized controlled trial evaluating TIGERTRIEVER™ 13 for medium vessel occlusion (MVO) ischemic stroke

Principal Investigators: Jeffrey Saver, MD (UCLA); Rishi Gupta, MD (Wellstar Health System); René Chapot, MD (Alfried Krupp Krankenhaus, Germany); David Fiorella, MD (Stony Brook University)

Key Results (Presented February 2026 at International Stroke Conference):

- Primary endpoint: 3-fold higher rate of successful reperfusion (86.3% vs 27.7%; P < .001)

- Safety: 0% symptomatic intracranial hemorrhage (sICH) in Tigertriever 13 arm

- Comparative sICH rates: 2-6% with IV thrombolysis alone in contemporary trials

- Significance: First thrombectomy device to demonstrate safe flow restoration in randomized MVO trial

Enrollment: Completed December 2025

SUCCESS Study - COMANECI™ for Aneurysms

- Prospective post-market U.S. study

- 95% successful long-term occlusion

- 1% retreatment rate

- Results presented at ESMINT Congress September 2024

Other Recent Publications (2025-2026)

- Early experience with Drivewire 24 (June 2025)

- Tigertriever 13 for distal MVO: Meta-analysis (June 2025)

- Anch'Or Harpoon Technique with Tigertriever 13 (June 2022)

Leadership Team

Executive Leadership

Chief Executive Officer & Co-founder: Ronen Eckhouse

- Co-founded Rapid Medical in 2008

- Led company through multiple financing rounds and global expansion

QA/RA Senior Director: Ina Gutman

- Oversees quality assurance and regulatory affairs

- Contact: ina.gutman@rapid-medical.com

Regulatory Status and Approvals (2026)

FDA Cleared: TIGERTRIEVER 13, 17, 21, 25; COMANECI; DRIVEWIRE 14, 24

CE Marked (EU MDR): TIGERTRIEVER 13, 17, 21, XL, 25; COMANECI; DRIVEWIRE 14, 24

Indications: Restoration of blood flow in acute ischemic stroke patients within 8 hours of symptom onset; temporary assist device for wide-necked intracranial aneurysm coiling; neurovascular access